Shirin Yaghoobpoor

Dr. Shirin Yaghoobpoor

Shahid Beheshti University of Medical Sciences, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in Life Sciences
Verified
Journal Article
Closed access
BFBahareh Farasati Far
Bahareh Farasati Far
KVKimia Vakili
Kimia Vakili
MFMobina Fathi
Mobina Fathi
SYShirin Yaghoobpoor
Shirin Yaghoobpoor
MBMohammed Bhia
Mohammed Bhia
MNMohammad Reza Naimi-Jamal
Mohammad Reza Naimi-Jamal

1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
GWGancheng Wang
Gancheng Wang
AMAzam Mivefroshan
Azam Mivefroshan
SYShirin Yaghoobpoor
Shirin Yaghoobpoor
SKShokoufeh Khanzadeh
Shokoufeh Khanzadeh
GSGoli Siri
Goli Siri
SASamira Alesaeidi
Samira Alesaeidi
The goal of this study was to conduct a systematic review of the literature on the relationship between peripheral blood platelet to lymphocyte ratio (PLR) and mortality in sepsis and to integrate the findings in a meta‐analysis. An electronic search of three main databases was performed: PubMed, Embase, and Scopus on 19 December 2021. Finally, 16 studies comprising 2403 septic patients, including 1249 survivors and 1154 nonsurvivors, were included in this meta‐analysis. We found that PLR levels were significantly higher in nonsurvivors than in survivors (random effect model: SMD = 0.72, 95% CI; 0.35–1.10, p < 0.001). However, significant heterogeneity was observed across the studies (I2 = 94.1%, p < 0.01). So, we used random effect model in our meta‐analysis. In the subgroup analysis, according to mortality time, patients deceased during one month after sepsis had elevated levels of PLR compared to survivors (SMD = 1.03, 95% CI = 0.15‐1.92, p = 0.22). However, in‐hospital mortality was not associated with PLR level (SMD = 0.41, 95% CI = −0.18‐0.99, p = 0.175). Our findings support PLR to be a promising biomarker that can be readily integrated into clinical settings to aid in the prediction and prevention of sepsis mortality.

28 September 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
MSMehrnaz Salahi
Mehrnaz Salahi
SPSina Parsa
Sina Parsa
DNDelaram Nourmohammadi
Delaram Nourmohammadi
ZRZahra Razmkhah
Zahra Razmkhah
OSOmid Salimi
Omid Salimi
NDNiloofar Deravi
Niloofar Deravi
Migraine headaches are highly prevalent, affecting 15% of the population. However, despite many studies to determine this disease's mechanism and efficient management, its pathophysiology has not been fully elucidated. There are suggested hypotheses about the possible mediating role of mast cells, immunoglobulin E, histamine, and cytokines in this disease. A higher incidence of this disease in allergic and asthma patients, reported by several studies, indicates the possible role of brain mast cells located around the brain vessels in this disease. The mast cells are more specifically within the dura and can affect the trigeminal nerve and cervical or sphenopalatine ganglion, triggering the secretion of substances that cause migraine. Neuropeptides such as calcitonin gene-related peptide (CGRP), neurokinin-A, neurotensin (NT), pituitary adenylate-cyclase-activating peptide (PACAP), and substance P (SP) trigger mast cells, and in response, they secrete pro-inflammatory and vasodilatory molecules such as interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) as a selective result of corticotropin-releasing hormone (CRH) secretion. This stress hormone contributes to migraine or intensifies it. Blocking these pathways using immunologic agents such as CGRP antibody, anti-CGRP receptor antibody, and interleukin-1 beta (IL-1β)/interleukin 1 receptor type 1 (IL-1R1) axis-related agents may be promising as potential prophylactic migraine treatments. This review is going to summarize the immunological aspects of migraine.

4 July 2022 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
MFMobina Fathi
Mobina Fathi
KVKimia Vakili
Kimia Vakili
SYShirin Yaghoobpoor
Shirin Yaghoobpoor
MQMohammad Sadegh Qadirifard
Mohammad Sadegh Qadirifard
MKMohammadreza Kosari
Mohammadreza Kosari
FSFatemeh Sayehmiri
Fatemeh Sayehmiri
Parkinson's disease (PD), the second most common neurodegenerative disorder, is characterized by neuroinflammation, formation of Lewy bodies, and progressive loss of dopaminergic neurons in the substantia nigra of the brain. In this review, we summarize evidence obtained by animal studies demonstrating neuroinflammation as one of the central pathogenetic mechanisms of PD. We also focus on the protein factors that initiate the development of PD and other neurodegenerative diseases. Our targeted literature search identified 40 pre-clinicalin vivoandin vitrostudies written in English. Nuclear factorkappaB (NF-kB) pathway is demonstrated as a common mechanism engaged by neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA), as well as the bacterial lipopolysaccharide (LPS). The α-synuclein protein, which plays a prominent role in PD neuropathology, may also contribute to neuroinflammation by activating mast cells. Meanwhile, 6-OHDA models of PD identify microsomal prostaglandin E synthase-1 (mPGES-1) as one of the contributors to neuroinflammatory processes in this model. Immune responses are used by the central nervous system to fight and remove pathogens; however, hyperactivated and prolonged immune responses can lead to a harmful neuroinflammatory state, which is one of the key mechanisms in the pathogenesis of PD.

20 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SYShirin Yaghoobpoor
Shirin Yaghoobpoor
MFMobina Fathi
Mobina Fathi
KVKimia Vakili
Kimia Vakili
ZTZohreh Tutunchian
Zohreh Tutunchian
MDMina Dehghani
Mina Dehghani
MHMohammadreza Hajiesmaeili
Mohammadreza Hajiesmaeili
Background: COVID-19 is a viral infectious disease leading to a spectrum of clinical complications, especially cardiovascular. Evidence shows that this infection can potentially accompany a worse outcome in pregnant women. Cardiovascular complications in mothers and their fetuses are reported by previous studies. Objective: In this systematic review, we aim to investigate the cardiovascular complications of COVID-19 during pregnancy in the mothers and fetus, according to the published literature. Method: We systematically searched the online databases of PubMed, Scopus, Web of Science, and Google Scholar, using relevant keywords up to April 2022. We included all observational studies reporting cardiovascular complications among COVID-19-affected pregnant women and their fetuses. Results: We included 74 studies containing 47582 pregnant COVID-19 cases. Pre-eclampsia, hypertensive disorders, cardiomyopathy, heart failure, myocardial infarction, thrombosis formation, alterations in maternal–fetal Doppler patterns, and maternal and fetal arrhythmia were reported as cardiovascular complications. The highest incidences of pre-eclampsia/eclampsia among COVID-19 pregnant cases, reported by studies, were 69% and 62%, and the lowest were 0.5% and 3%. The highest and lowest incidences of fetal bradycardia were 20% and 3%, and regarding fetal tachycardia, 5.4% and 1%, respectively. Conclusion: SARS-CoV-2 infection during pregnancy can potentially be associated with cardiovascular complications in the mother, particularly pre-eclampsia and heart failure. Moreover, SARS-CoV-2 infection during pregnancy can potentially cause cardiovascular complications in the fetus, particularly arrhythmia.

30 September 2020 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
NDNiloofar Deravi
Niloofar Deravi
MFMobina Fathi
Mobina Fathi
KVKimia Vakili
Kimia Vakili
SYShirin Yaghoobpoor
Shirin Yaghoobpoor
MPMarzieh Pirzadeh
Marzieh Pirzadeh
SGSamad Ghaffari
Samad Ghaffari
After the emergence of the novel 2019 coronavirus disease in P. R. China, this highly contagious disease has been currently spread out to almost all countries, worldwide. Novel 2019 coronavirus disease, Middle East respiratory syndrome, and severe acute respiratory syndrome are reported to cause a higher risk for severe infections in patients with chronic comorbidities, such as hypertension and diabetes. These severe infections can contribute to higher rates of morbidity and mortality in these patients. In the present review, we discussed the role and underlying mechanisms of the two most common chronic diseases, type-2 diabetes mellitus and hypertension, in clinical manifestations and disease severity of novel 2019 coronavirus disease, Middle East respiratory syndrome and severe acute respiratory syndrome, with the hope to provide evidence for better decision-making in the treatment of this vulnerable population.